Supplemental Digital Content 1: Table 1a and 1b
Average doses of (a) EC-MPS and (b) Cyclosporine levels by treatment groups (safety population)
a. Average daily dose of EC-MPS (mg) by time interval
Study Days Intensified N=213 n
mean (SD)
Standard N=219 n mean (SD)
Days 1-14 213
2725 (305.4) 219
1407 (116.4)
Days 15-28 199
2157 (346.7) 207
1407 (181.1)
Days 29-42 186
1991 (391.3)
198 1409 (179.3)
Days 43-56 183
1496 (286.6)
192 1395 (219.0)
Days 57-84 179
1402 (259.7) 189
1362 (222.7)
Days 85-120 175
1330 (284.7) 185
1341 (251.5)
Days 121-180 164
1290 (320.5)
177 1326 (258.8)
Overall 213
1711 (378.8)
219 1362 (172.5)
b. Cyclosporine levels (ng/mL)
Study
Days Cyclosporine target levels in patients receiving anti-
IL-2 receptor antibodies Cyclosporine target levels in patients not receiving anti-IL-2 receptor antibodies C0 levels [ng/mL] C2 levels [ng/mL] C0 levels [ng/mL] C2 levels [ng/mL]
Intensified N=162
mean (SD)
Standard N=162
mean (SD)
Intensifie d N=162 mean (SD)
Standar d N=162
mean (SD)
Intensifie d N=51 mean
(SD)
Standar d N=57 mean (SD)
Intensifie d N=51 mean (SD)
Standar d N=57 mean (SD) Day 10 221.2
(79.4)
230.6 (95.1)
1289.5 (461.2)
1316.1 (499.0)
366.0 (745.4)
253.9 (94.1)
1340.4 (436.9)
1305.4 (461.6) Day 42
Day 84
203.2 (125.5)
149.7 (61.7)
178.7 (72.42)
148.1 (58.27)
1257.1 (460.5) 1025.6 (345.9)
1184.3 (369.1) 831.6 (265.0)
269.8 (90.8) 212.7 (146.8)
284.3 (145.9)
208.3 (128.3)
1393.3 (442.82)
1086.4 (449.0)
1138.3 (596.6) 1047.3 (247.1) Day 180 135.6
(61.27)
130.0 (45.89)
837.7 (332.4)
752.9 (318.2)
218.7 (275.5)
173.7 (98.9)
972.0 (339.4)
789.6 (240.4)